NCT02485873View on ClinicalTrials.gov

Real-Life Evidence on Stroke Prevention in SPAF

CompletedOBSERVATIONAL

Enrollment

8,607

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions

Atrial Fibrillation (Prevention of Stroke)

Interventions

DRUG

Rivaroxaban (Xarelto, BAY59-7939)

As prescribed by treating physicians

DRUG

Vitamin K antagonists

As prescribed by treating physicians

Trial Locations (1)

Unknown

Many Locations

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

Janssen, LP

INDUSTRY

lead

Bayer

INDUSTRY

NCT02485873 - Real-Life Evidence on Stroke Prevention in SPAF | Biotech Hunter | Biotech Hunter